---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-25-002520"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:09:03.101337+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives

## Summary
- Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.
- Matthew Boyd promoted to Chief Regulatory Officer; Jill Buck to Chief Development Officer; Katherine Chan to Executive Director, Urology Clinical Lead.
- New board members have experience in gene therapy, oncology, and product launches; company advancing detalimogene toward planned commercialization.
- Board increased from seven to nine members after appointments; no disagreements cited for Bos resignation.
- Independent director compensation plan applies; indemnification agreements entered.

## SEC filing metadata
- accession: 0000929638-25-002520
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000092963825002520/0000929638-25-002520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000092963825002520/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-25-002520
- JSON: https://secwatch.observer/filing/0000929638-25-002520.json
- Plain text: https://secwatch.observer/filing/0000929638-25-002520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.